||Recombinant Human CADM2 (Accession # AAI06000) was produced in Mouse myeloma cell line, NS0-derived.
|Predicted N Terminal:
||Lyophilized from a 0.2 µm filtered solution in PBS.
||Measured by its ability to enhance neurite outgrowth of E16-E18 rat embryonic cortical neurons.Able to significantly enhance neurite outgrowth when immobilized as a 3 µL droplet containing 50 ng on a nitrocellulose-coated microplate.
||Recombinant Human CADM2 has a calculated MW of 35.5 kDa (monomer). In SDS-PAGE migrates as 36-55 kDa, reducing conditions.
||>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
||Avoid repeated freeze-thaw cycles. No activity loss was observed after storage at: In lyophilized state for 1 year (4ºC); After reconstitution under sterile conditions for 3 months (-70ºC).